|
1
|
Carbone DP, Ding K, Roder H, Grigorieva J,
Roder J, Tsao MS, Seymour L and Shepherd FA: Prognostic and
predictive role of the VeriStrat plasma test in patients with
advanced non-small-cell lung cancer treated with erlotinib or
placebo in the NCIC Clinical Trials Group BR.21 trial. J Thorac
Oncol. 7:1653–1660. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gaspar LE, Mehta MP, Patchell RA, Burri
SH, Robinson PD, Morris RE, Ammirati M, Andrews DW, Asher AL, Cobbs
CS, et al: The role of whole brain radiation therapy in the
management of newly diagnosed brain metastases: A systematic review
and evidence-based clinical practice guideline. J Neurooncol.
96:17–32. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bhatnagar AK, Flickinger JC, Kondziolka D
and Lunsford LD: Stereotactic radiosurgery for four or more
intracranial metastases. Int J Radiat Oncol Biol Phys. 64:898–903.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kirby N, Chuang C, Pouliot J, Hwang A and
Barani IJ: Physics strategies for sparing neural stem cells during
whole-brain radiation treatments. Med Phys. 38:5338–5344. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tarnawski R, Michalecki L, Blamek S,
Hawrylewicz L, Piotrowski T, Slosarek K, Kulik R and
Bobek-Billewicz B: Feasibility of reducing the irradiation dose in
regions of active neurogenesis for prophylactic cranial irradiation
in patients with small-cell lung cancer. Neoplasma. 58:507–515.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gondi V, Tolakanahalli R, Mehta MP,
Tewatia D, Rowley H, Kuo JS, Khuntia D and Tomé WA:
Hippocampal-sparing whole-brain radiotherapy: A ‘how-to’ technique
using helical tomotherapy and linear accelerator-based
intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys.
78:1244–1252. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wolff D, Abo-Madyan Y, Dobler B, Lohr F,
Mai S, Polednik M and Wenz F: Serial tomotherapy vs. MLC-IMRT
(multileaf collimator intensity modulated radiotherapy) for
simultaneous boost treatment large intracerebral lesions. Z Med
Phys. 19:58–66. 2009.(In German).
|
|
8
|
Langer CJ and Mehta MP: Current management
of brain metastases, with a focus on systemic options. J Clin
Oncol. 23:6207–6219. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mehta MP, Paleologos NA, Mikkelsen T,
Robinson PD, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS,
Gaspar LE, et al: The role of chemotherapy in the management of
newly diagnosed brain metastases: A systematic review and
evidence-based clinical practice guideline. J Neurooncol. 96:71–83.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tatar Z, Thivat E, Planchat E, Gimbergues
P, Gadea E, Abrial C and Durando X: Temozolomide and unusual
indications: Review of literature. Cancer Treat Rev. 39:125–135.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Addeo R, Caraglia M, Faiola V, Capasso E,
Vincenzi B, Montella L, Guarrasi R, Caserta L and Del Prete S:
Concomitant treatment of brain metastasis with whole brain
radiotherapy [WBRT] and temozolomide [TMZ] is active and improves
quality of life. BMC Cancer. 7:182007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu R, Wang X, Ma B, Yang K, Zhang Q and
Tian J: Concomitant or adjuvant temozolomide with whole-brain
irradiation for brain metastases: A meta-analysis. Anticancer
Drugs. 21:120–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
EuroQol Group, : EuroQol - a new facility
for the measurement of health-related quality of life. Health
Policy. 16:199–208. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ferro M, Cilla S, Macchia G, Deodato F,
Pierro A, Digesu C, Ferrandina G, Ciuffreda M, Sallustio G and
Morganti AG: On the cutting edge of intensity modulated
radiotherapy and simultaneous integrated boost (IMRT-SIB): The case
of a patient with 8 brain metastases. Rep Pract Oncol Radiother.
20:316–319. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Edwards AA, Keggin E and Plowman PN: The
developing role for intensity-modulated radiation therapy (IMRT) in
the non-surgical treatment of brain metastases. Br J Radiol.
83:133–136. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Slade AN and Stanic S: The impact of RTOG
0614 and RTOG 0933 trials in routine clinical practice: The US
Survey of Utilization of Memantine and IMRT planning for
hippocampus sparing in patients receiving whole brain radiotherapy
for brain metastases. Contemp Clin Trials. 47:74–77. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gondi V, Pugh SL, Tome WA, Caine C, Corn
B, Kanner A, Rowley H, Kundapur V, DeNittis A, Greenspoon JN, et
al: Preservation of memory with conformal avoidance of the
hippocampal neural stem-cell compartment during whole-brain
radiotherapy for brain metastases (RTOG 0933): A phase II
multi-institutional trial. J Clin Oncol. 32:3810–3816. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guerrieri M, Wong K, Ryan G, Millward M,
Quong G and Ball DL: A randomised phase III study of palliative
radiation with concomitant carboplatin for brain metastases from
non-small cell carcinoma of the lung. Lung Cancer. 46:107–111.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Robinet G, Thomas P, Breton JL, Léna H,
Gouva S, Dabouis G, Bennouna J, Souquet PJ, Balmes P, Thiberville
L, et al: Results of a phase III study of early versus delayed
whole brain radiotherapy with concurrent cisplatin and vinorelbine
combination in inoperable brain metastasis of non-small-cell lung
cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol
95-1. Ann Oncol. 12:59–67. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee DH, Han JY, Kim HT, Yoon SJ, Pyo HR,
Cho KH, Shin SH, Yoo H, Lee SH and Lee JS: Primary chemotherapy for
newly diagnosed nonsmall cell lung cancer patients with synchronous
brain metastases compared with whole-brain radiotherapy
administered first: Result of a randomized pilot study. Cancer.
113:143–149. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim DY, Lee KW, Yun T, Kim DW, Kim TY, Heo
DS, Bang YJ and Kim NK: Efficacy of platinum-based chemotherapy
after cranial radiation in patients with brain metastasis from
non-small cell lung cancer. Oncol Rep. 14:207–211. 2005.PubMed/NCBI
|
|
22
|
Neuhaus T, Ko Y, Muller RP, Grabenbauer
GG, Hedde JP, Schueller H, Kocher M, Stier S and Fietkau R: A phase
III trial of topotecan and whole brain radiation therapy for
patients with CNS-metastases due to lung cancer. Br J Cancer.
100:291–297. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang J, Stevens MF and Bradshaw TD:
Temozolomide: Mechanisms of action, repair and resistance. Curr Mol
Pharmacol. 5:102–114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Q, Jiang Z, Qi X, Lu S, Wang S, Leng
C, Lu F, Liu H, Liang S and Shi J: Whole brain radiation therapy
followed by intensity-modulated boosting treatment combined with
concomitant temozolomide for brain metastases from non-small-cell
lung cancer. Clin Transl Oncol. 16:1000–1005. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Addeo R, De Rosa C, Faiola V, Leo L,
Cennamo G, Montella L, Guarrasi R, Vincenzi B, Caraglia M and Del
Prete S: Phase 2 trial of temozolomide using protracted low-dose
and whole-brain radiotherapy for nonsmall cell lung cancer and
breast cancer patients with brain metastases. Cancer.
113:2524–2531. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gamboa-Vignolle C, Ferrari-Carballo T,
Arrieta Ó and Mohar A: Whole-brain irradiation with concomitant
daily fixed-dose temozolomide for brain metastases treatment: A
randomised phase II trial. Radiother Oncol. 102:187–191. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Verger E, Gil M, Yaya R, Viñolas N, Villà
S, Pujol T, Quintó L and Graus F: Temozolomide and concomitant
whole brain radiotherapy in patients with brain metastases: A phase
II randomized trial. Int J Radiat Oncol Biol Phys. 61:185–191.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Antonadou D, Paraskevaidis M, Sarris G,
Coliarakis N, Economou I, Karageorgis P and Throuvalas N: Phase II
randomized trial of temozolomide and concurrent radiotherapy in
patients with brain metastases. J Clin Oncol. 20:3644–3650. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hassler MR, Pfeifer W, Knocke-Abulesz TH,
Geissler K, Altorjai G, Dieckmann K and Marosi C: Temozolomide
added to whole brain radiotherapy in patients with multiple brain
metastases of non-small-cell lung cancer: A multicentric Austrian
phase II study. Wien Klin Wochenschr. 125:481–486. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chua D, Krzakowski M, Chouaid C, Pallotta
MG, Martinez JI, Gottfried M, Curran W and Throuvalas N:
Whole-brain radiation therapy plus concomitant temozolomide for the
treatment of brain metastases from non-small-cell lung cancer: A
randomized, open-label phase II study. Clin Lung Cancer.
11:176–181. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hamilton E and Infante JR: Targeting
CDK4/6 in patients with cancer. Cancer Treat Rev. 45:129–138. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cardama GA, Gonzalez N, Maggio J, Menna PL
and Gomez DE: Rho GTPases as therapeutic targets in cancer
(Review). Int J Oncol. 51:1025–1034. 2017. View Article : Google Scholar : PubMed/NCBI
|
